会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • NOVEL INDOLE OR INDAZOLE DERIVATIVE OR SALT THEREOF
    • 新颖的吲哚或吲哚衍生物或其盐
    • US20130289072A1
    • 2013-10-31
    • US13978632
    • 2012-01-06
    • Makoto KitadeShuichi OhkuboChihoko Yoshimura
    • Makoto KitadeShuichi OhkuboChihoko Yoshimura
    • C07D401/14C07D403/14
    • C07D401/14A61K31/4178A61K31/4439C07D403/14
    • The present invention relates to provision of a novel indazole compound which is capable of inhibiting HSP90 and shows a cytostatic effect on cancer cells. The present invention also relates to provision of a drug useful for preventing and/or treating, on the basis of an HSP90 inhibitory effect, a disease in which HSP90 participates, in particular, cancer. A compound represented by the general formula (I) or a salt thereof: wherein X represents CH or N; any one or two of Y1, Y2, Y3, and Y4 represent C—R3 or N, and the others represent CH; A and B are the same or different and represent an optionally substituted monocyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S, and O; R1 represents a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms etc.; R2 represents a hydrogen atom, a halogen atom etc.; R3 represents a hydrogen atom, a halogen atom etc.; R4 and R5 are the same or different and represent a hydroxyl group etc.; R6 and R7 are the same or different and represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms etc.; and R8 represents an optionally substituted cycloalkyl group having 3 to 7 carbon atoms etc.
    • 本发明涉及提供能够抑制HSP90并对癌细胞具有细胞抑制作用的新型吲唑化合物。 本发明还涉及提供可用于预防和/或治疗HSP90抑制作用的药物,其特征在于HSP90参与的疾病,特别是癌症。 由通式(I)表示的化合物或其盐:其中X表示CH或N; Y1,Y2,Y3和Y4中的一个或两个表示C-R3或N,其余的表示CH; A和B相同或不同,表示具有1至4个选自N,S和O的杂原子的任选取代的单环不饱和杂环基; R1表示氢原子,可以具有取代基的碳原子数1〜6的烷基等。 R2表示氢原子,卤素原子等; R3表示氢原子,卤素原子等; R4和R5相同或不同,表示羟基等。 R6和R7相同或不同,表示氢原子,碳原子数1〜6的烷基等。 R8表示可以具有取代基的碳原子数为3〜7的环烷基等。
    • 5. 发明申请
    • NOVEL BICYCLIC COMPOUND OR SALT THEREOF
    • 新型双环化合物或其盐
    • US20130296320A1
    • 2013-11-07
    • US13978613
    • 2012-01-06
    • Makoto KitadeSatoshi YamashitaShuichi Ohkubo
    • Makoto KitadeSatoshi YamashitaShuichi Ohkubo
    • C07D401/14C07D403/14C07D403/04C07D417/04C07D413/04C07D401/04C07D471/04
    • C07D403/04A61K31/4375A61K31/4709A61K31/4725A61K31/497A61K31/501A61K31/506A61K31/517A61K31/5377C07D401/04C07D401/14C07D403/14C07D413/04C07D417/04C07D471/04
    • Provided is a novel bicyclic compound which has an HSP90 inhibitory effect and a carcinostatic effect. Also provided is a pharmaceutical agent which is based on the HSP90 inhibitory effect and is useful in the prevention and/or treatment of a disease involving HSP90, particularly, cancer. The present invention provides a compound represented by the following general formula (I) or a salt thereof wherein at least one of X1, X2, X3, and X4 represents N or N-oxide and the rest thereof are the same or different and each represent C—R2; any one or two of Y1, Y2, Y3, and Y4 represent C—R4 and the rest thereof are the same or different and each represent CH or N; R1 represents an optionally substituted monocyclic or bicyclic unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, S, and O; R2 represents a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms etc.; R3 represents a hydrogen atom, —CO—R5 etc.; R4 represents a hydrogen atom, —CO—R6, —N(R7)(R8) etc.; R5 represents a hydroxyl group, an amino group etc.; R6 represents a hydroxyl group etc.; R7 and R8 are the same or different and each represent a hydrogen atom, an optionally substituted alkyl group having 1 to 6 carbon atoms etc.; and R9 represents an optionally substituted cycloalkyl group having 3 to 7 carbon atoms etc.
    • 提供具有HSP90抑制作用和制癌作用的新型双环化合物。 还提供了基于HSP90抑制作用的药剂,并且可用于预防和/或治疗涉及HSP90,特别是癌症的疾病。 本发明提供由以下通式(I)表示的化合物或其盐,其中X 1,X 2,X 3和X 4中的至少一个表示N或N-氧化物,其余的相同或不同,表示 C-R2; Y1,Y2,Y3和Y4中的任何一个或两个表示C-R 4,其余的相同或不同,各自表示CH或N; R1表示具有1至4个选自N,S和O的杂原子的任选取代的单环或双环不饱和杂环基; R2表示氢原子,可以具有取代基的碳原子数1〜6的烷基等。 R3表示氢原子,-CO-R5等; R4代表氢原子,-CO-R6,-N(R7)(R8)等; R5代表羟基,氨基等; R6表示羟基等。 R 7和R 8相同或不同,各自表示氢原子,可以具有取代基的碳原子数1〜6的烷基等。 R9表示碳原子数3〜7的任意取代环烷基等。
    • 9. 发明授权
    • Intimal hypertrophy inhibitors
    • US5977130A
    • 1999-11-02
    • US913237
    • 1997-09-10
    • Atsushi SatoTetsuji AsaoYuichi HagiwaraMakoto KitadeYasundo Yamazaki
    • Atsushi SatoTetsuji AsaoYuichi HagiwaraMakoto KitadeYasundo Yamazaki
    • A61K31/404A61K31/407A61P9/10C07D209/34C07D401/06C07D401/14C07D471/04A61K31/40A61K31/44
    • C07D401/06C07D209/34C07D401/14C07D471/04
    • The present invention is directed to an intimal hypertrophy inhibitor containing as the active ingredient an oxyindole derivative represented by the following formula (I) or a salt thereof: ##STR1## (wherein R.sup.1 represents a hydrogen atom; a phenyl group which may be substituted by a lower alkyl group, a lower alkoxy group, a lower alkylaminoalkoxy group, a hydroxy group, an amino group, a lower alkylamino group, or a halogen atom; or a pyridyl group which may be substituted by a lower alkyl group, a lower alkoxy group, a lower alkylaminoalkoxy group, a hydroxy group, an amino group, a lower alkylamino group, a halogen atom, a lower alkoxycarbonyl group, or a carboxyl group; R.sup.2 represents a phenyl group which may be substituted; or a pyridyl group which may be substituted by a lower alkyl group, a lower alkoxy group, a lower alkylaminoalkoxy group, a hydroxy group, an amino group, a lower alkylamino group, a halogen atom, a lower alkoxycarbonyl group, or a carboxyl group; R.sup.3 represents a hydrogen atom; a lower alkyl, benzyl, or a benzenesulfonyl group which may be substituted; or an acyl group; R.sup.4 represents a hydrogen atom; a lower alkoxy group, a halogen atom, an amino group, a lower alkylamino group, a carboxyl group, a lower alkoxycarbonyl group; a phenylcarbomoyl group which may be substituted; or a trifluoromethyl group; X represents CH or N; n represents a number between 0 and 4 inclusive that indicates the number of substituents; and the broken/solid double line denotes a single bond or a double bond). The intimal hypertrophy inhibitor of the present invention exhibits excellent inhibitory action against intimal hypertrophy, and thus is useful as a preventive/therapeutic/ameliorating agent for proliferative vascular diseases such as restenosis after PTCA, arteriosclerosis, peripheral embolism, and angiitis.